INTRODUCTION

77
Malignant melanoma is a cancer arising from melanocytes, and the incidence is rising 78 globally (1, 2). According to clinical factors and molecular profiles, melanoma is 79 subdivided into four subtypes: cutaneous melanoma with chronic sun-induced damage, 80 cutaneous melanoma without chronic sun-induced damage, acral melanoma (AM) and 81 mucosal melanoma (3, 4). In Caucasians, the major subtype of melanoma is non-acral 82 cutaneous melanoma, and the prevalence of acral and mucosal melanoma is only 83 about 5% and 1% respectively (5, 6). In asian populations the major subtypes of 84 melanoma are acral and mucosal melanoma, which comprise more than 70% of all 85 melanomas (7). Up to date, successful therapeutics for advanced or metastatic acral 86 melanoma has not been established. Targeted therapies using inhibitors specific for Table S6 ). However, more males tended to harbor Ccnd1 gain than females did; and 284 patients with ulceration were more likely to contain Ccnd1 aberrations ( Table 2 ). The whereas that without Cdk4 gain was 3 mm (range: 0.1-40.0 mm) (P < 0.0001; Table   287 2). Moreover, the median thickness of AM with any CDK4 pathway aberrations (≥ 1 288 CNV) was more than that of AM without any CDK4 pathway aberrations (P < 0.0001; 289 control SK-Mel-5 cells) were resistant after 24h treatments (Fig. 2D) . AT7519 and 328 LEE011 showed comparable inhibitory efficiency on AMC-1; AT7519 and 329 PD0332991 showed comparable inhibitory efficiency on AMC-3 and SK-Mel-5; 330 Moreover, at lower concentration (less than 2 μM), AT7519 tended to show stronger 331 inhibitory effect on AMC-1, AMC-3 and SK-Mel-5 (Fig. 2) . Similar effects were 332 observed for these inhibitors when used at a single dose at both 24h and 48h after 333 treatments (Supplementary Fig. S2) . Moreover, when compared to the chemotherapy 334 drug dacarbacine (DTIC), the pan-CDK inhibitor AT7519 tended to be more efficient 335 than DTIC in SK-Mel-5, AMC-1 and AMC-3 cells (Supplementary Fig. S2 ). These 336 data indicate that AM cells may be responsive to pan-CDK inhibitors despite that 337 highly selective CDK4/6 inhibitors also elicit inhibitory effects to lesser extent. (Fig. 2) . Meanwhile, the cell 342 lines (A2058, AMC-4 and AMC-5), containing no CDK4 pathway aberrations as 343 either Cdk4 gain or Ccnd1 gain, could not be inhibited by CDK4/6 inhibitors 344 regarding cell viability (Fig. 2) .
345
It was surprising to observe that all the CDK4/6 inhibitors did not work equally 346 well in inhibiting cell viability (Fig. 2) . So we examined the inactivation of Rb 
the observed inhibitory effects for CDK4/6 inhibitors (in Fig. 2) 
363
Since AT7519 and PD0332991 showed more robust inhibition of cell viability in 364 vitro (Fig. 2) , we treated the PDX models with AT7519 and PD0332991. As compared 365 to the buffer-treated group, AT7519 and PD0332991 showed no inhibitory effect on 366 tumor growth in PDX-017 model without CDK4 pathway aberrations (Fig. 3A and   367 
3B
). AT7519 and PD0332991 could significantly inhibit the growth of PDX-012 368 model with Cdk4 gain plus P16 INK4a loss ( Fig. 3C and 3D) , PDX-015 model with
369
Ccnd1 gain plus P16 INK4a loss (Fig. 3E and 3F) , and almost eliminate the tumor of 370 PDX-001 model with Cdk4 gain plus Ccnd1 gain ( Fig. 3G and 3H) . Moreover,
371
AT7519 but not PD0332991 could elicit inhibitory effects on tumor growth of 372 PDX-006 models with Cdk4 gain (Fig. 3I and 3J ). The appearance of tumor nodules 373 after the treatments was shown in Supplementary Fig. S4 , showing the efficacy of 374 CDK4/6 inhibitors in inhibiting AM tumor growth in vivo.
375
As further evidence, we examined the proliferation of AM cells in PDX models after treatments by immunohistochemical staining of Ki-67 (Fig. 4) . In consistent with 377 the results of tumor volume changes ( Fig. 3; Supplementary Fig. S4) (Fig. 4C) , Ccnd1 gain 380 plus P16 INK4a loss (Fig. 4D) , Cdk4 gain plus Ccnd1 gain (Fig. 4E) or Cdk4 gain (Fig.   381 4F), but not in PDX model without CDK4 pathway aberrations (Fig. 4B) There are limitations, unresolved concerns and potential perspectives in our study.
441
As an initial screening assay of CDK4 pathway aberrations, only the CNVs of Cdk4, counted. Bar = 50 μm. The results of Ki-67 + cells (B-F) were presented as mean ± SE of three sections. ns, P > .05; *, P < .05; **, P < .01; ***, P < .001 (One-way ANOVA followed by Bonferroni multiple comparison).
